1Q FY2007(Fiscal Year Ending March 31, 2008)

Financial Results
Presentation

July 31, 20071

Safe Harbor Statement•

Materials and information provided during this presentation may contain socalled “forward-looking statements.” These statements are based on current
expectations, forecasts and assumptions that are subject to risks anduncertainties which could cause actual outcomes and results to differ materiallyfrom these statements.

•Risks and uncertainties include general industry and market conditions, andgeneral domestic and international economic conditions such as interest rateand currency exchange fluctuations. Risks and uncertainties particularly applywith respect to product-related forward-looking statements. Product risks anduncertainties include, but are not limited to, technological advances and patents
attained by competitors; challenges inherent in new product development,
including completion of clinical trials; claims and concerns about product safetyand efficacy; obtaining regulatory approvals; domestic and foreign healthcare
reforms; trends toward managed care and healthcare cost containment; andgovernmental laws and regulations affecting domestic and foreign operations.

•Also, for products that are approved, there are manufacturing and marketingrisks and uncertainties, which include, but are not limited to, inability to build
production capacity to meet demand, unavailability of raw materials, and failure
to gain market acceptance.

•The Company disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future eventsor otherwise.
2

1Q Consolidated Performance(billions of yen, %)1Q FY2006

Results%
100.0

Net Income

153.9
26.8
127.1
24.4
78.7
24.1
25.1
15.8

R&D +
Operating Income48.5

EPS (yen)

55.4

Net Sales
Cost of Sales
Gross Profits
R&D Expenses
SG&A Expenses
Operating Income
Ordinary Income

1Q FY2007

Results%

YOY (%) Change

100.0

114

22.1

15.6

103

0.7

84.4

117

21.4

17.3

125

6.2

52.2

117

13.2

14.9

109

2.1

16.1

113

3.3

10.3

176.0
27.5
148.5
30.5
91.8
26.2
28.4
19.3

11.0

122

3.5

31.5

56.7

32.2

117

8.2

123

12.6

17.4
82.6
15.8
51.1
15.7
16.3

68.1

3

Sales of Major Products(billions of yen, %)Products

Area

Total

Aricept®
Alzheimer’s disease
treatmentAcipHex®/Pariet®
Anti-ulcer agent
(PPI)

Japan
US
$ million
EuropeAsia
TotalJapanUS$ million
EuropeAsia

1Q FY2006
Results

53.7
11.5
33.1
289
7.7
1.4
40.5
7.1
29.3
256
3.0
1.1

1Q FY2007
Results
YOY (%)

67.3
14.9
41.5
343
9.2
1.8
44.9
8.9
31.8
263
2.5
1.6

125
130
125
119
119
129
111
125109103841464

Sales to Customers
by Geographic Area
(billions of yen, %)1Q FY2006
Results

1Q FY2007%

Results%

YOY (%) ChangeJapan

70.9

46.1

78.3

44.5

110

7.3

North America

65.742.776.8

43.6

117

11.1

Europe

12.4

8.0

14.1

8.0

114

1.7

Asia, Oceania &Middle East

4.9

3.2

6.9

3.9

141

2.0

Overseas total

83.0

53.9

97.8

55.5

118

14.8

Total

153.9

100.0

176.0

100.0

114

22.1

5

Operating Incomeby Geographic Area
1Q FY2006(billions of yen, %)1Q FY2007

Results%

Results%

YOY (%) Change

Japan

17.0

69.0

23.0

78.3

135

5.9

North America

6.0

24.3

4.1

14.0

69(1.9)Europe0.7

3.0

0.6

2.1

82(0.1)

Asia, Oceania &Middle East

0.9

3.8

1.7

5.7

178

0.7Overseas

7.7

31.0

6.4

21.7

83(1.3)

Sub Total

24.7

100.0

29.4

100.0

119

4.7

Elimination/Corporate(0.6)

(3.2)

Total

24.1

26.2

(2.6)
109

2.16

Performance of Eisai Inc.

(millions of dollars, %)1Q FY2006
Results

Net Revenue
Aricept®
AcipHex®
Zonegran®
Fragmin®
Oncology products(ONTAK®, etc.)
Operating Income
Net Income
Operating Income(Pre-royalty deduction)

1Q FY2007%

Results

576
289
256
916

100.0%YOY (%) Change

100.01126853.3

11954

40.9

103

80.9

64(3)

2.8644343
2636121.873(4)

--

10

1.6-

1048
34

8.4

4.661(19)

5.8

29
22

3.4

65(12)

132

23.0

149

23.1

112

16

50.3
44.4
1.5

7

U.S. Business (1)Preparations for Launch of E7389• Target Subpart H NDA Submission in 3Q FY2007• Global Oncology Strategy– Medical and Marketing• Global Medical & Marketing Services facilitates global oncology strategy– API Production• Process validation of 3 batches
at P1 building at Kashima Plant isongoing• Commercial production
to begin after validation– Production• Construction of the new oncologyparenteral facility in North Carolina
initiated• Validation to start in FY2009(Initial commercial production to beoutsourced)

New Oncology Parenteral Facility
in North Carolina Production Site8

U.S. Business (2)Preparations for Launch of E7389• Started Preparation for Launch in U.S– Participation in Scientific Meetings• Aims to increase scientific presence of Eisai
in oncology through participationin conferences such as ASCO andSan Antonio Breast Cancer Symposium– Oncology Team• Core team that consists of production,ASCO 2007
logistics, marketing, sales support, reimbursement,
and medical education is preparing to execute the US oncology strategy
for E7389 including selection of the brand name– Sales and Marketing• Plans to have field force of approximately 150 (Oncology Teamand Hospital Team)• Aims to prepare for managed care reimbursement

9European BusinessContinuous New Product Launches and Expansion into New Countries•

Newly launched(Lennox-Gastaut Syndrome)•– Germany, Austria, Sweden, Denmark, Norway, Finland, Iceland
Acquired commercialization rights for NeuroBloc® (cervical dystonia) fromSolstice Neurosciences, Inc.
– Exclusive commercialization rights in 35 European countries– Plan to start sales in October 2007•

Newly launchedintrathecal analgesia)(severe, chronic pain in patients who require– Sweden, Denmark, Norway, Finland, Iceland, Spain•

Solid growth of existing products– Aricept®, continuous growth: 119% (YOY)– Zonegran®, rapid expansion: ¥737 Mil. 262% (YOY)– Pariet®, assumed marketing responsibilities: Sweden, Denmark, Finland, Iceland•Expansion into new countries in FY2007– Initiated planning to expand to Russia, Czech Republic, Slovakia, Poland and Hungary– Planning to extend to 22 countries in FY2007(Zonegran)(Prialt)(Inovelon)(Neurobloc)

10

Asia, Oceania and the Middle East Business
Expand Asian Contribution to Profits• High growth of Aricept® and Pariet®
– Aricept®: 129%, Pariet®: 146% (YOY)• Humira® (rheumatoid arthritis)– Smooth launch in Korean & Taiwanese markets
Korea: Launched in April. Increased presence of Humira through participationin congresses and exhibitions
Taiwan: Launched in April. Progress in the listing of Humira on in-houseprescription formularies in key hospitals• Glufast® (a rapid-acting insulin secretagogue)– Acquired exclusive development and commercialization rights of Glufast® in 10
ASEAN countries in June
– Preparing submission for approval in 10 ASEAN countries• Gasmotin® (gastroprokinetic agent ）– Submitted a dossier to Thailand FDA• Zonegran® (epilepsy)– Received product registration in Australia in June, applied for the price listing
11

Chinese Business
Revolutionary change in Sales and Marketing•

China as an independent business unit in Asia
– Positioning China as the most critical market for our future growth byimplementing a distinct management system within Asian region•

Revolutionary change in sales and marketing– Actively enforcing marketing (small meetings and information provision) with
an emphasis on compliance (460 MRs)
– Established two departments under marketing headquarters to enhance
MR’s competence and provide the highly detailed tactical assistancerequired by MRs•

Enhance accuracy and speed of decision-making andinformation transmission & collection– Chinese sales market divided into threeregions (Beijing area, Shanghai area
and Guangzhou area) and 11 territories(previously 7 regions and 90 territories)•Heilongjiang

JilinNeimenggu
Xinjiang

Liaoning
Beijing
Tianjin
ShanxiNingxia

Hebei

RegionShandong
Qinghai

Gansu
Shaanxi

Jiangsu
Anhui

XizangEnrich product portfolio to achieve the targetof Dramatic Leap Plan
– Enrich human resources of business development (BD)and accelerate collaboration with Global BD to expedite
licensing opportunities

Beijing

Henan

Hubei
SichuanChongqing

Guizhou

Shanghai

Shanghai

Zhejiang
Hunan

Jiangxi

Guangdong

FujianYunnanGuangxi

TaiwanGuangdongHong Kong

Hainan12Japanese Business (1)Good Sales of Aricept® and Pariet®, and Solid Growth ofLocomotory System and Cardiovascular Products• Prescription pharmaceuticals business achieved 11% sales growth• Outperformed the market growth by 3 points (IMS)• Actonel® once-weekly formulation launched
Achieved more than 50% sales growth compared to the previous period• Tambocor® received an additional indication for paroxysmal atrial fibrillation/flutter
Contributes to disease management by preventing cardioembolic stroke• Nitrol® injection syringe launched
Improves usability and safety managementin treatment• Pariet® for h. pylori secondary eradication passed
the final reviewing process (Pharmaceutical Affairsand Food Sanitation Council) by MHLW

Nitrol injection syringe• A treatment for insomnia, Lunesta® (U.S. brand name) licensed from Sepracor Inc.
Eisai will conduct Phase II and later studies in Japanand plans to file for approval by the end of Dramatic Leap Plan

13

Japanese Business (2)Aricept® to be Approved for Severe Alzheimer’s
Disease in Japan Following the US Approval
Aricept® for severe Alzheimer’s disease (AD) passed the final reviewing
process (Pharmaceutical Affairs and Food Sanitation Council) byMHLW
Severe AD

Mild to Moderate AD– Aricept® will become a treatment for
all stages of AD - mild, moderateand severe– Dosage and administration:
increase to 10mg dose after 5mg
for severe AD– Enhance information provision
activities for psychiatric clinics,
nursing homes, healthcare facilities
and group homes for the elderly

Healthcare facilities for the elderly
Group homes
Nursing homes
Home care

Aricept®-treatedpatients

Additional
indication forsevere AD

Family doctor, general hospitals (clinics that support home care)

Key hospitals, university hospitals
Psychiatric clinics

14Novel Anti-tumor Mechanism ofE7107
Published in Nature Chemical Biology•“RNA Splicing” – Novel anti-tumor mechanism- E7107 is believed to modulate the function of splicing factor SF3b by
impairing splicing and inhibiting tumor cell growth- Exploring effect in cases resistant to existing oncology treatment
O•

Novel chemical structure

NN- Chemically modified “pladienolide” becomes E7107
HO H

H

H3C

•

OH

Prominent activity against tumors

H 3C HO
H HO CH3

H 3CH
HCH3OHCH3OOHOH- Observed tumor regression effects inmany cancer types in mice transplantedwith human cancer cells- Observed complete tumor regression in some mice•Phase I study commencing in U.S. and Europe

15

Novel Anti Tumor Mechanism
Controlling Splicing

Exon
IntronPre-mRNA

CellNuclear

E7107

snＲＮＡ
Splicing factor

SF3b sn ＲＮＡ

Splicing

spliceosome

Mature mRNA

Protein synthesis necessary forcancer cells
Anti-tumor effect16